Japan· JP-4490033F2059
ビラスチン
A bilastin product containing ビラスチン, registered in Japan by 陽進堂ホールディングス, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Bilastin is registered in 11 of 19 countries.
Countries holding a registration under ATC R06AX29 (bilastin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Bilastin · ATC R06AX29
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of bilastin costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.14 in France to $0.45 in Switzerland — a ×3.3 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Bilastin · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.45
- FR France$0.14
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ビラスチン
- Manufacturer
- 陽進堂ホールディングス
- Country
- Japan (JP)
- ATC code
- R06AX29
- ATC class
- Bilastin
- Defined daily dose
- 20 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under R06AX29
Bilastin, as other registers publish it.
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
- CzechiaABISAXGlenmark Pharmaceuticals s.r.o., Praha
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d90e4190-442d-4f77-a0f6-6cf35c71c50d GET /v1/drugs/d90e4190-442d-4f77-a0f6-6cf35c71c50d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "20mg1錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4490033F2059",
"category": "内用薬",
"price_yen": 14859,
"generic_name": "ビラスチン",
"product_name_jp": null,
"therapeutic_class": "4490",
"transitional_expiry": "14859"
}See everything about bilastin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.